UnitedHealth Group is a leading diversified health and well-being company that provides a wide range of health care products and services. The company operates through two main segments: UnitedHealthcare, which offers health insurance and health services to individuals and businesses, and Optum, which delivers pharmacy care, health management, and technology solutions. UnitedHealth Group focuses on enhancing health care access, improving health outcomes, and optimizing costs through integrated care solutions and data-driven insights. With a commitment to innovation and quality, the company aims to help people live healthier lives while making the health care system work better for everyone. Read More
Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 7.1% in the afternoon session after the company trimmed the upper end of its 2025 revenue forecast, citing a delay in vaccine shipments. The company pointed to a delay in vaccine deliveries to the United Kingdom, which it pushed into the first quarter of 2026. This news overshadowed second-quarter results that beat Wall Street expectations. For the quarter, Moderna's revenue dropped about 41% from the previous year to $142 million, driven by lower sales of its COVID-19 vaccine. Despite the revenue decline, the company successfully narrowed its net loss as its cost-cutting measures took effect. Adding to the pressure, Moderna also announced plans to reduce its workforce by 10% and confirmed a delay in the U.S. approval for its combined COVID-flu vaccine until 2026.
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance.
Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
The appointment of Wayne DeVeydt as CFO comes amid an operational reset at UnitedHealth, following a sharp downgrade in its 2025 earnings outlook and a more than 50% drop in its stock price this year.
UnitedHealth Group (NYSE: UNH) today announced Wayne S. DeVeydt has been appointed its chief financial officer, effective September 2, 2025. John F. Rex, who joined the company in 2012 and has been CFO since 2016, will become strategic advisor to the CEO on the same date.
UnitedHealth Group Inc. (NYSE: UNH) shares are trading lower Thursday, after Baird downgraded the stock to Underperform and slashed its price target from $312 to $198.
President Donald Trump has announced a new private health tracking system, aimed at streamlining patient access to health records and wellness monitoring.
Shares of medical device company Penumbra (NYSE:PEN)
jumped 11.8% in the afternoon session after the company reported impressive second-quarter financial results that surpassed analyst expectations and raised its full-year revenue forecast. The company posted revenue of $339.5 million, a 13.4% increase year-over-year, which beat the consensus estimate of $327.77 million. Earnings per share also came in strong at $0.86, topping expectations of $0.83. This growth was primarily fueled by its U.S. Thrombectomy business, which involves procedures to remove blood clots and saw a 22.6% revenue jump. The embolization segment, which deals with blocking blood flow for treatment, also performed well. Bolstered by this strong performance, Penumbra lifted its full-year 2025 revenue guidance, signaling confidence in its continued growth trajectory.
While BofA sees long-term upside for UnitedHealth, it has applied a lower multiple due to near-term uncertainty around Medicare Advantage and OptumHealth margins.
Healthcare company, UnitedHealth Group Inc. (NYSE: UNH), says that it will drop 600,000 Medicare Advantage members and launch a sweeping operational overhaul after being blindsided by $6.5 billion in unanticipated medical costs.
UnitedHealth’s short-term margin challenges are steep, but the company’s strategic leadership changes and long-term earnings forecast suggest a possible rebound by 2026.
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector.
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector.
A number of stocks fell in the afternoon session after industry bellwether UnitedHealth Group (UNH) slashed its 2025 profit forecast after reporting a significant surge in medical costs, sending shockwaves across the health insurance sector. The core of the issue stems from an “unprecedented medical cost trend environment,” particularly within the Medicare Advantage market, which are privately run versions of the federal health insurance program. UnitedHealth, the largest provider in this space, now expects these costs to rise by 7.5% in 2025, a significant jump from its earlier 5% projection, with the potential to accelerate to almost 10% in 2026. In response, the insurer announced it will drop plans covering over 600,000 people. The company's lowered earnings forecast has raised investor concerns that these surging costs and utilization rates are an industry-wide problem, impacting the profitability of other carriers as well.
